IQVIA Holdings Inc. - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. IQVIA Holdings Inc. is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. As of September 30, 2025, the company had approximately 91,000 employees operating in over 100 countries.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenues | $4,100 | $3,896 | $11,946 | $11,447 |
| Net Income (Attributable to IQVIA) | $331 | $285 | $846 | $936 |
| Diluted EPS | $1.93 | $1.55 | $4.86 | $5.08 |
| Operating Cash Flow (YTD) | $1,919 | $1,831 | $1,919 | $1,831 |
| Total Debt (Principal) | $15,034 | $14,045 | $15,034 | $14,045 |
| Cash and Equivalents | $1,814 | $1,572 | $1,814 | $1,572 |
| Effective Tax Rate (YTD) | 18.3% | 16.8% | 18.3% | 16.8% |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenues increased 5.2% ($204 million) year-over-year, driven by constant currency growth of 3.9%. YTD revenue growth was 4.4% ($499 million), with constant currency growth of 3.7%.
- Profitability: Net income attributable to IQVIA increased 16.1% in Q3 ($331 million vs. $285 million). However, YTD net income decreased 9.6% ($846 million vs. $936 million) primarily due to a $14 million loss in equity earnings from unconsolidated affiliates and higher interest expenses.
- Segment Performance:
- Technology & Analytics Solutions: Q3 revenue up 5.0%; segment profit down 8.6% due to higher costs.
- Research & Development Solutions: Q3 revenue up 4.5%; segment profit flat (-0.4%). Backlog increased to $32.4 billion.
- Contract Sales & Medical Solutions: Q3 revenue up 16.1%; segment profit up 8.3%.
- Debt Structure: Total indebtedness increased to $15.0 billion. The company issued $2.0 billion in 6.250% Senior Notes due 2032 in June 2025 and refinanced existing Term B loans. Interest expense increased to $189 million in Q3 (from $170 million) due to higher outstanding debt balances.
- Restructuring: Restructuring costs were $20 million in Q3 and $81 million YTD, aimed at reducing overcapacity and integrating acquisitions.
Guidance, Outlook, and Risks
- Outlook: Management expects restructuring actions to continue through 2025 and into 2026. The company anticipates approximately $8.1 billion of its $32.4 billion Research & Development Solutions backlog will convert to revenue in the next 12 months.
- Capital Allocation: The Board increased the stock repurchase authorization by $2.0 billion in February 2025. During the first nine months of 2025, the company repurchased 6.4 million shares for $1.032 billion. Approximately $1.981 billion remains authorized for repurchase.
- Legal Proceedings: The long-standing legal dispute with Veeva Systems, Inc. was fully resolved in August 2025 with no payments exchanged between parties.
- Tax Environment: The U.S. enacted the "One Big Beautiful Bill Act" (OBBBA) in July 2025, extending provisions of the Tax Cuts and Jobs Act. Management does not expect a material impact on 2025 financial statements. The OECD Pillar Two global minimum tax (15%) is in effect but has not had a material impact to date.
- Risks: Key risks include foreign currency fluctuations (approx. 30% of revenue is non-USD), potential termination of client contracts, data privacy regulations, and the ability to successfully integrate acquisitions.
Investor Verification Checklist
- Debt Servicing Capacity: Verify the impact of the new $2.0 billion Senior Notes and refinanced Term B loans on future interest coverage ratios, given the rise in interest expense.
- Backlog Conversion: Monitor the conversion rate of the $32.4 billion Research & Development Solutions backlog, specifically the $8.1 billion expected in the next 12 months.
- Cost Management: Assess whether the $81 million in YTD restructuring costs will yield the expected margin improvements in 2026, particularly in the Technology & Analytics segment where profit declined despite revenue growth.
- Foreign Currency Exposure: Review hedging strategies given that 30% of revenues are denominated in foreign currencies, which significantly impacts reported results.
- Share Repurchase Pace: Evaluate the sustainability of the aggressive share repurchase program ($1.032 billion YTD) against the company's debt load and cash flow generation.